Όλο το DSpace

Πλοήγηση ανά Θέμα "itraconazole"

Αποτελέσματα 1-6 από 6

    • Aspergillosis in immunocompromised patients with haematological malignancies 

      Gletsou E., Ioannou M., Liakopoulos V., Tsiambas E., Ragos V., Stefanidis I. (2018)
      Aspergillosis, which is saprophytic in nature, is known to cause massive destruction of paranasal sinuses in immunocompromised hosts, but in immunocompetent individuals invasive aspergillosis is rare. Diagnosis is posed ...

    • Efficacy of Antimicrobial Treatment in Dogs with Atopic Dermatitis: An Observational Study 

      Sofou E.I., Aleksandrova S., Badulescu E., Chatzis M., Saridomichelakis M. (2022)
      There is a shortage of studies reporting the efficacy of antimicrobial treatment of dogs with atopic dermatitis (AD) and skin infections (SIs). The aim of this study was to evaluate the change in the severity of skin lesions ...

    • Encapsulating peritoneal sclerosis: Pathophysiology and current treatment options 

      Jagirdar R.M., Bozikas A., Zarogiannis S.G., Bartosova M., Schmitt C.P., Liakopoulos V. (2019)
      Encapsulating peritoneal sclerosis (EPS) is a life-threatening complication of long-term peritoneal dialysis (PD), which may even occur after patients have switched to hemodialysis (HD) or undergone kidney transplantation. ...

    • Index of Suspicion 

      Nazarian; Kaditis, A. G.; Papadimitriou, E.; Alexopoulos, E.; Skenteris, N.; Gidvani, V. K.; Crouch, G.; Pino, J.; Baptist, E. C.; Deol, K. K.; Nageswaran, S.; Glock, M. S.; Hill, I. D.; Ermis, B.; Ors, R.; Kardas, F. (2004)

    • Pesticides and cardiotoxicity. Where do we stand? 

      Georgiadis N., Tsarouhas K., Tsitsimpikou C., Vardavas A., Rezaee R., Germanakis I., Tsatsakis A., Stagos D., Kouretas D. (2018)
      Cardiovascular diseases are among the most significant causes of mortality in humans. Pesticides toxicity and risk for human health are controlled at a European level through a well-developed regulatory network, but ...

    • Upadacitinib tartrate in rheumatoid arthritis 

      Stamatis P., Bogdanos D.P., Sakkas L.I. (2020)
      does not achieve low disease activity or remission despite the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or biological DMARDs (bDMARDs). The Janus kinase (JAK) inhibitors are the ...